e-learning
resources
European Respiratory Review
2008
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure
Klein M., Schermuly R. T., Ellinghaus P., Milting H., Riedl B., Ghofrani H. A., Grimminger F., Schafer S.
Source:
Eur Respir Rev 2008; 17: 72-73
Journal Issue:
June 2008 - 17 (108)
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Klein M., Schermuly R. T., Ellinghaus P., Milting H., Riedl B., Ghofrani H. A., Grimminger F., Schafer S.. Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure. Eur Respir Rev 2008; 17: 72-73
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2013; 41: 224-232
Year: 2013
Effects of erythropoietin on advanced pulmonary vascular remodelling
Source: Eur Respir J 2008; 31: 126-134
Year: 2008
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
Inhibition of p38 MAPK improves heart function in experimental pressure-overload induced right ventricular hypertrophy and failure
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014
The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target
Source: Eur Respir J 2011; 38: 1453-1460
Year: 2011
Chronic thromboembolic pulmonary hypertension: role of medical therapy
Source: Eur Respir J 2013; 41: 985-990
Year: 2013
Genetics of pulmonary hypertension: from bench to bedside
Source: Eur Respir J 2002; 20: 741-749
Year: 2002
Chronic thromboembolic pulmonary hypertension: animal models
Source: Eur Respir J 2013; 41: 1200-1206
Year: 2013
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
Activation of AMPK inhibits pulmonary arterial remodeling
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept